High-risk prostate cancer: The rationale for brachytherapy

被引：0
|
作者：
Blasko, John C.
机构：
来源：
ONCOLOGY-NEW YORK | 2008年 / 22卷 / 09期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：1016 / 1017
页数：2
相关论文
共 50 条
  • [1] HDR brachytherapy for high-risk prostate cancer
    Lo, TCM
    Bouyounes, BT
    Goodman, N
    Bihrle, W
    Roth, RA
    CANCER JOURNAL, 2001, 7 (06): : 527 - 527
  • [2] HDR Brachytherapy in the Management of High-Risk Prostate Cancer
    Masson, Susan
    Persad, Raj
    Bahl, Amit
    ADVANCES IN UROLOGY, 2012, 2012
  • [3] The rationale for adjuvant chemotherapy for high-risk prostate cancer
    Kent, EC
    Hussain, MHA
    CURRENT OPINION IN UROLOGY, 2003, 13 (02) : 123 - 131
  • [4] High-dose rate brachytherapy for high-risk prostate cancer
    Schenck, M.
    Krause, K.
    Schwandtner, R.
    Haase, I.
    Fluehs, D.
    Friedrich, J.
    Jaeger, T.
    Boergermann, C.
    Ruebben, H.
    Stuschke, M.
    UROLOGE, 2006, 45 (06): : 715 - +
  • [5] Brachytherapy boost and cancer-specific mortality in favorable high-risk versus other high-risk prostate cancer
    Muralidhar, Vinayak
    Xiang, Michael
    Orio, Peter F., III
    Martin, Neil E.
    Beard, Clair J.
    Feng, Felix Y.
    Hoffman, Karen E.
    Nguyen, Paul L.
    JOURNAL OF CONTEMPORARY BRACHYTHERAPY, 2016, 8 (01) : 1 - 6
  • [6] Brachytherapy boost and cancer-specific mortality in favorable high-risk and other high-risk prostate cancer.
    Muralidhar, Vinayak
    Xiang, MIchael H.
    Orio, Peter F.
    Martin, Neil E.
    Beard, Clair
    Feng, Felix Yi-Chung
    Hoffman, Karen E.
    Nguyen, Paul L.
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (02)
  • [7] Interstitial brachytherapy should be standard of care for treatment of high-risk prostate cancer
    Bittner, Nathan
    Merrick, Gregory S.
    Wallner, Kent E.
    Butler, Wayne M.
    ONCOLOGY-NEW YORK, 2008, 22 (09): : 995 - 1004
  • [8] Dose escalation with HDR brachytherapy for intermediate- and high-risk prostate cancer
    Chicas-Sett, R.
    Celada, F.
    Burgos, J.
    Farga, D.
    Perez-Calatayud, M.
    Roldan, S.
    Collado, E.
    Ibanez, B.
    Perez-Calatayud, J.
    Tormo, A.
    RADIOTHERAPY AND ONCOLOGY, 2017, 123 : S380 - S381
  • [9] High-risk prostate cancer treated with I-125 brachytherapy.
    Stockham, Abigail Lauren
    Reddy, Chandana A.
    Stephans, Kevin L.
    Ciezki, Jay P.
    Tendulkar, Rahul D.
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (05)
  • [10] The radiosensitivity index predicts benefit from HDR brachytherapy in high-risk prostate cancer
    Thiruthaneeswaran, N.
    Bibby, B. A. S.
    Pereira, R.
    More, E.
    Denley, H.
    Henry, A.
    Wylie, J.
    Hoskin, P.
    Bristow, R.
    Choudhury, A.
    West, C.
    RADIOTHERAPY AND ONCOLOGY, 2020, 152 : S1086 - S1087
12345